Mikko Ora
 Senior Lecturer


mikora@utu.fi

+358 29 450 3196

+358 50 328 5911



TyöhuoneK219


ORCID-tunnistehttps://orcid.org/0000-0001-5125-6127





Asiantuntijuusalueet
Orgaaninen kemia; Kinetiikka; Nukleotidit; Aihiolääkkeet

Biografia

FM 1994; FT 1999 (Bioorgaaninen kemia); Dosentti 2006 (Fysikaalinen orgaaninen kemia)

Yliopistonlehtori 2006 -



Tutkimus

Structurally modified nucleotides have received attention as a means to combat against viral infections, cancer and hereditary diseases. The research is focused on pro-drug models of nucleotides. The goal is to develop the degradable lipophilic carriers which are used to improve the cellular membrane penetration of the negatively charged nucleotides. To obtain mechanistic information on the chemical hydrolysis and enzymatic cleavage of the protecting groups, the kinetic studies of the pro-drugs are of interest.


The small RAS oncoproteins play a crucial role in human cancers and are, hence, a target in anticancer drug discovery. In spite of numerous efforts, a direct small-molecule signalling inhibitor drug of mutant RAS has not been able to develop. The aim of the study is to provide a potent method to suppress oncogenic RAS signalling with phosphotriester derivatives.



Opetus

KEMI6110 Orgaaninen kemia

KEMI6124 LuK-harjoitustyö/Orgaaninen kemia ja kemiallinen biologia



Julkaisut
  
null
  
null
  
1/2
  
null
  
null
  


Last updated on 2023-12-07 at 12:13